{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:42:27Z","timestamp":1772120547722,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.cgh.2011.09.017","type":"journal-article","created":{"date-parts":[[2011,10,2]],"date-time":"2011-10-02T10:02:06Z","timestamp":1317549726000},"page":"46-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model"],"prefix":"10.1016","volume":"10","author":[{"given":"Corey A.","family":"Siegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel R.G.","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna N.A.","family":"Tosteson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2011.09.017_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ibd.20029","article-title":"Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940\u20132000","volume":"13","author":"Loftus","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2011.09.017_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2011.09.017_bib3","first-page":"S-77","article-title":"Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study","volume":"24","author":"Allaart","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cgh.2011.09.017_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2011.09.017_bib5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2011.09.017_bib6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2011.09.017_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2011.09.017_bib8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cgh.2006.05.020","article-title":"Risks and benefits of infliximab for the treatment of Crohn's disease","volume":"4","author":"Siegel","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2011.09.017_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","article-title":"An evaluation of utility measurement in Crohn's disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2011.09.017_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2011.09.017_bib11","first-page":"463","article-title":"Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL)","volume":"16","author":"Uyl-de Groot","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cgh.2011.09.017_bib13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1572-0241.2008.01836.x","article-title":"Immunosuppressant medications and mortality in inflammatory bowel disease","volume":"103","author":"Lewis","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2011.09.017_bib15","series-title":"Data on file","year":"2009"},{"key":"10.1016\/j.cgh.2011.09.017_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2011.09.017_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2011.09.017_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cgh.2010.04.023","article-title":"The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all","volume":"8","author":"Melmed","year":"2010","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356511010214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356511010214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:09:11Z","timestamp":1761541751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356511010214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1542356511010214"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2011.09.017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13477046.14857163","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2011.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}